Cargando…

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis

BACKGROUND: The Chinese government implemented the first round of National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China in 2019. This study aims to examine the impact of “4 + 7” policy on the price of policy-related drugs. METHODS: This study used drug purch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ni, Yang, Ying, Xu, Luxinyi, Mao, Zongfu, Cui, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524972/ https://www.ncbi.nlm.nih.gov/pubmed/34663282 http://dx.doi.org/10.1186/s12889-021-11882-7

Ejemplares similares

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series
por: Long, Hongfei, et al.
Publicado: (2022)

The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis
por: Yang, Ying, et al.
Publicado: (2021)

The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
por: Yang, Ying, et al.
Publicado: (2021)

Impact of ‘4+7’ volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China
por: Wang, Jing, et al.
Publicado: (2022)

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
por: Chen, Lei, et al.
Publicado: (2020)

The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis
por: Wang, Xiao, et al.
Publicado: (2023)

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis
por: Wen, Xiaotong, et al.
Publicado: (2021)

Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls
por: Chen, Yilin, et al.
Publicado: (2021)

The Effects of a New Public Medicine Procurement Policy on Medicine Price in Shaanxi Province, Western China: An Interrupted Time Series Analysis
por: Hu, Shuchen, et al.
Publicado: (2019)

The change of drug utilization in China’s public healthcare institutions under the “4 + 7” centralized drug procurement policy: Evidence from a natural experiment in China
por: Lu, Jiancheng, et al.
Publicado: (2022)

Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China
por: Zhao, Xinyu, et al.
Publicado: (2022)

A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China
por: Wen, Xiaotong, et al.
Publicado: (2023)

Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
por: Zhang, Wen, et al.
Publicado: (2023)

Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study
por: Cai, Lele, et al.
Publicado: (2022)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
por: Zhu, Hong, et al.
Publicado: (2022)

Reevaluation of adverse drug reactions of psychiatric drugs under the chinese drug volume-based procurement policy
por: Du, Zhiqiang, et al.
Publicado: (2022)

Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis
por: Sun, Yan, et al.
Publicado: (2022)

Healthcare professionals’ knowledge, attitude and practice towards National Centralized Drug Procurement policy in central China: A cross-sectional study
por: Huang, Anqi, et al.
Publicado: (2022)

Drug procurement, the Global Fund and misguided competition policies
por: Tren, Richard, et al.
Publicado: (2009)

Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China
por: Yuan, Jing, et al.
Publicado: (2021)

Factors influencing global antiretroviral procurement prices
por: Wirtz, Veronika J, et al.
Publicado: (2009)

Impact of China’s National Centralized Drug Procurement Policy on pharmaceutical enterprises’ financial performance: a quasi-natural experimental study
por: Sun, Zhixuan, et al.
Publicado: (2023)

Impact of the Low-Price Medicine Policy on Medicine Supply in China: An Interrupted Time-Series Analysis
por: Zhao, Mingyue, et al.
Publicado: (2021)

The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis
por: Rong, Xuejing, et al.
Publicado: (2020)

Impact of China’s zero mark-up drug policy on drug cost of NCDs’ outpatients: an interrupted time series analysis
por: Du, Jielin, et al.
Publicado: (2021)

Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study
por: Wang, Xiaoyang, et al.
Publicado: (2023)

The impacts of the “4+7” pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study
por: Wen, Xiaotong, et al.
Publicado: (2022)

The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis
por: Ding, Yi, et al.
Publicado: (2022)

Impact of the Drug Prices Control Order (2013) on the Utilization of Anticancer Medicines in India: An Interrupted Time-Series Analysis
por: Sharma, Bhavna, et al.
Publicado: (2022)

The Pricing of Breakthrough Drugs: Theory and Policy Implications
por: Levy, Moshe, et al.
Publicado: (2014)

Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004–2011
por: Luo, Jing, et al.
Publicado: (2014)

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study
por: Guan, Xiaodong, et al.
Publicado: (2019)

Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Drug pricing policies in one of the largest drug manufacturing nations in the world: Are affordability and access a cause for concern?
por: Ahmad, Akram, et al.
Publicado: (2015)

The impact of key monitoring policy on the usage of policy-related drugs in Hubei Province, China
por: Wen, Xiaotong, et al.
Publicado: (2023)

CERN Procurement Strategy and Policy
Publicado: (2011)

The impact of zero markup drug policy on patients' healthcare utilization and expense: An interrupted time series study
por: Zhu, Zheng, et al.
Publicado: (2022)

Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016–2018: an interrupted time series study in Shaanxi
por: Yan, Kangkang, et al.
Publicado: (2020)

The Impact of a National Stewardship Policy on the Usage Patterns of Key Monitoring Drugs in a Tertiary Teaching Hospital: An Interrupted Time Series Analysis
por: Li, Haiyan, et al.
Publicado: (2022)

Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis
por: Morrow, Richard L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_voq3qadvfo4gsurgerg3r2r6su